Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial - Tuttle, K R; Lakshmanan, M C; Rayner, B (Lancet Diabetes Endocrinol, 2018)
et al.